17hon MSN
AstraZeneca’s Enhertu (trastuzumab deruxtecan) emerged as the highest-selling new drug in India in 2024, generating Rs 58 ...
AstraZeneca on Thursday warned that it could be fined millions of dollars in importation tax fines as Chinese authorities ...
Roche has secured a new FDA approval for its first companion diagnostic test aimed at identifying breast cancer patients with ...
A pharma industry group asked the FDA to "take action" against a "dangerous" ad Hims & Hers plans to run during the Super ...
Indicates growing incidence of cancer among Indian population; five out of top 20 new brand launches are cancer drugs ...
Earnings per share excluding some items surged to $2.09, Astra said Thursday, higher than the $2.04 estimated by analysts ...
AstraZeneca on Thursday said it could face a fine of up to $4.5 million in China over suspected unpaid import taxes, raising ...
Evening Standard on MSN11d
AstraZeneca ‘very disappointed’ after ditching £450m Liverpool vaccine siteIt said the taxes related to its Imfinzi and Imjudo drugs, but could possibly widen to breast cancer drug Enhertu as well.
AstraZeneca is expecting Phase III trial data for seven new medicines in 2025, its CEO said as he confirmed the company’s ...
The boss of AstraZeneca has denied a rift with the Government after axing plans for a £450m vaccine factory in Liverpool. Sir ...
AstraZeneca PLC (NASDAQ:AZN – Free Report) – Equities researchers at Leerink Partnrs decreased their Q1 2025 EPS estimates for AstraZeneca in a research report issued to clients and investors ...
but could possibly widen to breast cancer drug Enhertu as well. The firm is continuing to co-operate with Chinese authorities. AstraZeneca appointed a new president for its China business late ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results